Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I have in past expressed my difficulty with deciding between TDG or Madoff, the suspicion is now Madoff more than ever.
The market is increasingly rejecting the EMA 85% chance of approval thesis.
Don't know when, but in principle yes.
Nice to see that Kathy Skoff of Anavex is updating clinicaltrials.gov. Perhaps going forward we can expect that Anavex keeps the information up to date and consistent with what the company does as says in other contexts.
The point though was that he was not there to stop Missling from declaring all
endpoints met.
Kun Jin is more than likely responsible for the much later “the trial was successful because” avenue.
Anavex have been planning to release a peer reviewed PDD trial data publication for over 3 years now.
Are you imaging integrity in Missling?
I like the confidence of inexperienced and hope you too are right.
Also 19 applications were withdrawn mostly because the applicant was unable to answered feedback and requests from the CHMP team at the process clock stops.
I would want to be the business advisor to anyone who’d want me as their advisor.
You must be one the make believe satisfied $AVXL investors clinging onto the 85% chance story.
I just think that as a ‘real’ $AVXL investor you are not very well up to speed on the facts.
Not a good rescue attempt either.
Well Kun Jin wasn't there to guard the Dec 1st 2022 met all endpoints bs!
Cause he can't admit failure.
You do realise, I hope, that with posts like that you are not supposed or even allowed to own $AVXL shares.
Delayed data releases are usually an indication that results are not that great.
A lot of those 'pages' are generated from databases of trial and other data points.
Most of those pages will never be read by any human, but AI should help regulators discover hidden issues that so far have often gone by,
Yes just a matter of for which outcome 😀
I still that I want see an MAA filed and accepted before deciding, if that doesn’t happen I think I am done.
Once a WGT member always must be biased, in the script I imagine.
At least it is not a P2/3 potential pivotal retail lure this time.
Another huge and meaningful trial that will give solid insights into Misslings modus operandi, if nothing else. And it splits that huge n between placebo and drug in two parts, so the results will be very malleable lending itself to all sorts of cool post hoc analysis and wonderful conclusions to carry on from.
Salary for years in the making here.
If you wait you can always buy $AVXL cheaper. Just ask damp powder boy,
Not quite sure what the contention is here, so I’ll agree with your point too.
Who is on the company's SAB or are employees of whatever reputation will have no baring on facts that can be established, which is what the case and court will be relying on.
One needs to add to that the time it will take Anavex to respond satisfactorily, which hopefully they can, to CHMP feedback and requests at the two process clock stops.
You'll be fine as there is absolute no problem with Anavex and Missling has got your back, WGT!!!
I can't help that fact appear scary to some.
Just as with a misunderstood 85% chance of EMA approval there are many factors to figure in, that are not yet known, as to whether the case against Anavex will be more than a distraction or a costly potentially devastating situation for the company.
Hopefully the company has a good D&O insurance.
There are many reasons for dismissal from outright to abandoned and several in between.
Settled means the company paid something to make the case go away, but does not necessarily equal quilt.
We could make this mb into a details class in many subjects, but I doubt there would be many dedicated top students attending.
A very comprehensive review of 2021 cases specifically against U.S. Life Sciences companies: Developments in Securities Fraud Class Actions Against U.S. Life Sciences Companies
That is far from correct, easily tested and disproven.
Ah but that he did.
Cut'n'paste MB artists doesn't add any knowledge to the field.
Not quite how it works.
Yes that Missling have said and it may well have induced investor excited as we know from this MB, but it probably isn't relevant from making a case stick.
That would require quantification!
The law firm filing first is likely not deeply in to biotech understanding. It doesn't matter too much at this stage. Pay attention towards May 14th as the lead plaintiff deadline expires for more thorough worked out motions for lead plaintiff from other law firms. If there no additional law firms with a plaintiff joining the case, then that would also be a signal that the case is unattractive.
People here get baffled about this every year.
Discovery if granted and giving access to eg. the SAP is the only way to potentially make a case that the company’s statements about the AVATAR trial and endpoints were false or the company omitted material information.
I will be looking for the wording of the company’s defence lawyers motion to dismiss.
If denied, then what will the amended and consolidated complaint cause say based on information gained during discovery?
Either way that should help to dismiss or confirm investor suspicions of the Anavex approach to clinical trials and their readouts.